Pelthos Therapeutics Inc. 8-K Filings

Pelthos Therapeutics Inc. determined that its condensed consolidated financial statements for the quarter ended March 31, 2026 can no longer be relied upon due to a misapplication of ASC 820 in valuing Level 3 fair value measurements of its convertible debt. After reassessing the valuation methods and inputs during the June 30, 2026 fair value measurement, the company concluded a restatement of that interim period is required.

The restatement will increase the fair value of convertible debt liabilities by $15.8 million, reduce accumulated other comprehensive income by $1.0 million, and increase accumulated deficit by $14.8 million. It will also add $14.8 million of non-cash expense to other expense and reduce other comprehensive loss by $1.0 million related to instrument credit risk. These changes affect net loss and loss per share but do not affect liquidity, cash, revenues, operating expenses, or operating loss.

The company identified a material weakness in internal control over financial reporting as of March 31, 2026, relating to controls over Level 3 fair value measurements of convertible debt and the Convertible Notes Subordination Agreement provisions. Disclosure controls and procedures were not effective, and Pelthos plans to outline remediation steps in an amended Q1 2026 report and its Q2 2026 report.

Pelthos Therapeutics Inc. furnished an update as its CEO prepares to present and hold investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. The accompanying presentation highlights Pelthos as a commercial-stage biopharmaceutical company focused on cutaneous infectious diseases, led by its at-home molluscum treatment ZELSUVMI.

The deck notes that Zelsuvmi launched in July 2025 and has seen strong uptake, with more than 20,000 units dispensed from launch through April 2026, 16,774 prescribed units and 4,867 unique prescribers. As of May 11, 2026, the company lists a stock price of $26.85, approximately $240 million market capitalization and $32.0 million of cash at the end of Q1 2026.

Pelthos also emphasizes recent acquisitions of two FDA-approved dermatology products, XEPI for impetigo and XEGLYZE for head lice, with anticipated commercial launches in early 2027 and mid-2027. Management highlights overlapping prescriber call points, 64 sales territories covering about 53% of molluscum claims, and payer coverage where 70% of combined Medicaid and commercial lives are under one Zelsuvmi contract.

Pelthos Therapeutics Inc. reported two key corporate governance changes. The board’s Audit Committee dismissed CBIZ CPAs P.C. as independent registered public accounting firm and approved the appointment of Grant Thornton LLP for the fiscal year ending December 31, 2026. The company states CBIZ’s prior audit reports for 2024 and 2025 contained no adverse opinions, disclaimers, or qualifications, and there were no disagreements or reportable events through May 18, 2026.

The company also detailed a Separation and Release Agreement with former Chief Financial Officer, Treasurer, and Secretary Francis Knuettel II, whose employment ended April 10, 2026. Under the agreement, he will receive earned but unpaid compensation, reimbursement of business expenses, separation pay equal to 12 months of base salary, or $430,000, and accelerated vesting of certain stock options and RSUs that would have vested in the 12 months after the separation date, subject to the agreement becoming effective after a seven‑day revocation period.

Pelthos Therapeutics Inc. reported first quarter 2026 results that show rapid ZELSUVMI growth but continued losses. Net product revenue for ZELSUVMI reached $10.7 million, up about 17% from $9.1 million in the fourth quarter of 2025, with total revenue of $10.9 million for the quarter.

ZELSUVMI dispensed units increased from 6,312 in the prior quarter to 7,884 in the first quarter of 2026, a 25% rise, and cumulative ZELSUVMI net sales since its July 2025 launch reached $26.9 million. The company expanded its sales force to 64 territory managers to support commercialization.

Pelthos remains unprofitable, posting a net loss of $10.2 million and Adjusted EBITDA of negative $8.0 million for the quarter. Cash and cash equivalents were $32.0 million as of March 31, 2026, supported by a $50.0 million senior secured term loan facility, of which $30.0 million was drawn in January 2026.

Pelthos Therapeutics Inc. furnished a press release and investor presentation highlighting its commercial dermatology portfolio and recent operating trends. The company markets ZELSUVMI for molluscum contagiosum, with a wholesale acquisition cost of $2,008.50 and launches of Xepi and Xeglyze planned for late 2026 and first half 2027. The presentation notes Pelthos as a commercial-stage biopharmaceutical company with a stock price of $24.00, approximately 8.9 million shares of common stock on an as-converted basis and a market capitalization of about $215 million. Cash at the end of 2025 was $18 million, excluding $30 million of 5‑year term notes issued in January 2026, and the company references an active $200 million shelf registration statement. Management reports revenue increased 28% quarter over quarter, while SG&A expenses declined 5% and adjusted EBITDA loss improved 22%, with personnel expenses expected to rise by about $1 million per quarter in 2026 to support sales expansion.

Pelthos Therapeutics Inc. has appointed John M. Gay as Chief Financial Officer, treasurer and secretary, effective April 10, 2026, succeeding Francis Knuettel II. Gay previously served as Senior Vice President, Finance & Accounting and brings more than 25 years of public company finance and accounting experience.

Under a new employment agreement, Gay will receive a base salary of $425,000 and be eligible for an annual bonus targeted at 40% of base salary, tied to goals set by the company and board. The company expects to enter into a separation agreement with Knuettel under his existing contract, and states his termination did not result from any disagreement on operations, policies or practices. A press release announcing the transition was furnished as an exhibit.

Pelthos Therapeutics Inc. reported its fourth-quarter and full-year 2025 results, showing a rapid commercial ramp for its lead product ZELSUVMI and expansion of its dermatology portfolio. ZELSUVMI net product revenue reached $16.2 million from launch in July 2025 through December 31, including $9.1 million in the fourth quarter, while total 2025 revenue including licensing was $16.8 million. Prescribers wrote 8,948 ZELSUVMI units in 2025 from 2,712 unique prescribers, with dispensed units rising 129% quarter over quarter. Pelthos acquired FDA‑approved XEPI for impetigo in November 2025 and XEGLYZE for head lice in January 2026, positioning a three-product pediatric-focused infectious skin franchise. To fund growth, the company closed an $18.0 million private convertible notes financing in November 2025 and entered a $50.0 million senior secured term loan in January 2026, drawing $30.0 million. Cash was $18.0 million as of December 31, 2025. Despite this progress, Pelthos reported a 2025 net loss of $43.3 million, including a $21.7 million loss in the fourth quarter, driven by high selling and administrative expenses, a non-cash $15.0 million fair value loss on convertible debt, and ongoing investments in commercialization.

Pelthos Therapeutics Inc. entered into a venture loan and security agreement with Horizon Technology Finance, providing a senior secured term loan facility of up to $50.0 million. The company drew $30.0 million at closing, with up to an additional $20.0 million available upon achieving specified milestones, to support commercialization of ZELSUVMI, launches of Xepi and Xeglyze, and general corporate purposes.

The loans bear interest at the prime rate plus 3.75%, with the prime rate floored at 6.75%, and include an interest-only period through at least February 1, 2029, potentially extended to February 1, 2030 if trailing twelve-month consolidated net revenue reaches $75.0 million. The facility matures on January 31, 2031 and is secured by substantially all borrower assets. As part of the financing, Pelthos issued Horizon warrants to purchase 65,488 common shares at an exercise price of $27.49 per share, exercisable for five years.

Pelthos Therapeutics Inc. updated how it pays its non-employee directors, following a review by its compensation committee and approval by the board. Effective January 1, 2026, board members receive an annual cash retainer of $40,000, while the non-executive chairman receives $60,000. Committee retainers include $7,000 for audit committee members and $19,000 for the audit chair, $5,000 for compensation committee members and $15,000 for its chair, and $4,000 for nominating and corporate governance committee members and $12,000 for its chair.

The company notes that non-employee directors may receive an initial equity grant under its 2023 Equity Incentive Plan when they first join the board, at the board’s discretion, but they do not receive annual equity awards for ongoing service. Pelthos also furnished, but did not file, an investor presentation on its website as of January 12, 2026, highlighting that this information is provided under Regulation FD and is not incorporated into other securities filings unless specifically referenced.

Pelthos Therapeutics Inc. entered into an Asset Purchase Agreement with Hatchtech Pty Ltd under which Pelthos bought all rights to the Xeglyze Product, a head lice treatment using Abametapir, and related intellectual property, regulatory materials, and tangible assets. The aggregate purchase price is $1,800,000, consisting of a $450,000 down payment made on November 20, 2025 and a $1,350,000 cash payment made on December 23, 2025. Pelthos obtained contractual rights to claw back up to 100% of the purchase price for certain seller defaults and if closing had not occurred by December 29, 2025. The transaction was consummated on the agreed closing date, and Pelthos plans to issue a press release announcing the closing.

Pelthos Therapeutics Inc. expanded its Board of Directors from seven to eight members and appointed Andrew J. Einhorn as a new independent director. Einhorn, an experienced biotech and pharmaceutical finance executive, will serve until the company’s 2026 annual meeting of shareholders. Effective December 23, 2025, he joined the Audit Committee and the Compensation Committee. For his board service, he will receive standard non-employee director compensation and an equity grant of 12,000 restricted stock units, each representing one share of common stock, which will vest on January 1, 2027. The company also entered into a standard indemnification agreement with him and issued a press release announcing his appointment.

Pelthos Therapeutics Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 17, 2025. As of the November 24, 2025 record date, 3,086,681 common shares were outstanding and entitled to vote, and holders representing 2,528,857 votes were present, constituting a quorum.

Stockholders elected seven directors to serve until the 2026 annual meeting, approved waiving the NYSE American limit on the number of common shares that may be issued to holders of the company’s senior secured convertible notes, and ratified CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Pelthos Therapeutics Inc. filed a current report to let investors know it has released a press release with its financial results for the three and nine months ended September 30, 2025, and an update on its operations. The press release is included as Exhibit 99.1.

The company states that this earnings information and the exhibit are being "furnished" rather than "filed," which affects how they are treated under securities laws. The same information is also referenced for Regulation FD disclosure, signaling that Pelthos is using the press release and this report to provide broad, simultaneous access to its latest quarterly and year‑to‑date results.

Pelthos Therapeutics Inc. announced a private financing and product acquisition. The company completed a senior secured convertible note financing for gross proceeds of approximately $18.0 million. The notes bear 8.5% interest, mature on November 6, 2027, and are initially convertible at $34.442 per share, with an automatic reduction to $29.73 on the later of December 1, 2025 and shareholder approval, if then above that level. Beneficial ownership limits cap conversions to 49.9% for Ligand and 4.99% or 9.99% for other investors.

Investors also received a 5.0% royalty on net sales of Xepi and rights to certain Sato-related payments, and the notes are secured by a lien on specified revenue streams. Pelthos entered a registration rights agreement to file a resale registration within 60 days and seek effectiveness by 90 days or two business days after a no-review notice. Separately, Pelthos acquired the Xepi assets from Biofrontera for up to $10.0 million, including $3.0 million cash at closing, $1.0 million upon availability of commercial quantities, and contingent milestones, and signed an exclusive Ferrer/Interquim license and supply agreement for Xepi in the U.S. territory.

Pelthos Therapeutics Inc. (PTHS) furnished an investor presentation under Item 7.01 (Regulation FD) in a Form 8-K. The presentation, dated October 14, 2025, is attached as Exhibit 99.1 and was also made available on the company’s website. The company emphasizes that this information is being furnished, not filed, and therefore is not subject to Section 18 liabilities, nor is it incorporated by reference except as specifically stated.

The presentation includes forward-looking statements disclaimer language under the Private Securities Litigation Reform Act, covering topics such as commercialization progress, clinical development, market opportunities, intellectual property, and strategy execution. The filing reiterates that these statements involve risks and uncertainties and that the company undertakes no obligation to update them except as required by law.

Pelthos Therapeutics filed an 8-K/A to amend its prior Current Report to attach unaudited condensed financial statements of LNHC, Inc. as of June 30, 2025 and 2024 and for the three- and six-month periods ended June 30, 2025 and 2024, plus unaudited pro forma condensed combined financial information for Pelthos for the six months ended June 30, 2025 and year ended December 31, 2024, in connection with the Merger. The amendment also attaches a schedule of material agreements and exhibits, including the Agreement and Plan of Merger, Securities Purchase Agreement, Registration Rights Agreement, various license and manufacturing agreements, and a Transition Services Agreement. The filing discloses beneficial ownership details showing a large holder with approximately 49.0% beneficial ownership and summarizes board composition, committee memberships, executive officers, and identified business risks including regulatory approval, supply-chain and commercialization concentration risks.

Pelthos Therapeutics Inc. is highlighting its story to investors by presenting at the Wells Fargo 2025 Healthcare Conference in Boston. The company’s Chief Executive Officer, Scott Plesha, and Chief Financial Officer, Francis Knuettel II, are scheduled to present on September 3, 2025, at 1:30 p.m. Eastern Time.

A live webcast and 90-day replay will be available on Pelthos’ website, giving investors access to management’s update on its product pipeline and recent business developments, including the commercial launch of ZELSUVMI. The company also furnished a press release and Q3 2025 presentation as exhibits, which include forward-looking statements about its launch execution, pipeline progress, intellectual property protection, and ability to carry out its development strategy amid various business and macroeconomic risks.

Pelthos Therapeutics Inc. filed a current report to furnish a press release issued on August 18, 2025. The press release summarizes financial results for the company’s legacy operations for the three and six months ended June 30, 2025 and also provides an update on its therapeutic programs.

The press release is included as Exhibit 99.1, and the company states that this information is being furnished, not filed, under the securities laws, which affects how it is treated for liability and incorporation by reference purposes.